It has been shown that human group IIa secreted phospholipase A2 (sPLA2), found at high levels in inflammatory fluids, displays direct bactericidal properties against Gram-positive bacteria, while activity against Gram-negative bacteria requires the complement system or additional co-factors produced by neutrophils. Pseudomonas aeruginosa, an increasingly prevalent opportunistic human pathogen, is the most common Gram-negative rod found in cystic fibrosis lung infections, where it is associated with an inflammatory environment. Because murine intestinal group II sPLA2 produced by Paneth cells has been shown to be directly bactericidal against Gram-negative bacteria, IIa sPLA2 activity against P. aeruginosa clinical isolates was evaluated and provides the first evidence that the enzyme can be fully bactericidal in a concentration- and time-dependent manner against Gram-negative rods. Furthermore, it was demonstrated that these bactericidal properties were unaffected by high protein and salt concentrations, as observed in cystic fibrosis secretions, and that bacterial killing paralleled phospholipid hydrolysis. Finally, no cytotoxicity was observed when IIa sPLA2 was incubated with human pulmonary cells, highlighting its potential use to synergize bactericidal antibiotics by promoting sublethal alterations of the bacterial cell wall.
BucklandA. G,
HeeleyE. L,
WiltonD. C.2000; Bacterial cell membrane hydrolysis by secreted phospholipases A2: a major physiological role of human group IIa sPLA2 involving both bacterial cell wall penetration and interfacial catalysis. Biochim Biophys Acta1484195–206[CrossRef]
DavidsenJ,
JorgensenK. Andersen,
LT,
MouritsenO. G.2003; Secreted phospholipase A2 as a new enzymatic trigger mechanism for localised liposomal drug release and absorption in diseased tissue. Biochim Biophys Acta160995–101[CrossRef]
DoggettR. G,
HarrisonG. M,
StillwellR. N,
WallisS. E.1966; An atypical Pseudomonas aeruginosa associated with cystic fibrosis of pancreas. J Pediatr 68:215–221[CrossRef]
ElsbachP,
WeissJ,
LevyO.1994; Integration of antimicrobial host defenses: role of the bactericidal/permeability-increasing protein. Trends Microbiol 2:324–328[CrossRef]
GiwercmanB,
LambertP. A,
RosdahlV. T,
ShandG. H,
HoibyN.1990; Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially derepressed β-lactamase producing strains. J Antimicrob Chemother 26:247–259[CrossRef]
HancockR. E,
WongP. G.1984; Compounds which increase the permeability of the Pseudomonas aeruginosa outer membrane. Antimicrob Agents Chemother 26:48–52[CrossRef]
KoduriR. S,
GrönroosJ. O,
LaineV. J. O,
Le CalvezC,
LambeauG,
NevalainenT. J,
GelbM. H.2002; Bactericidal properties of human and murine groups I, II, V, X and XII secreted phospholipases A2. J Biol Chem2775849–5857[CrossRef]
LaineV. J. O,
GrassD. S,
NevalainenT.2000; Resistance of transgenic mice expressing human group II phospholipase A2 to Escherichia coli infection. Infect Immun 68:87–92[CrossRef]
LemnaouarM,
ChastreE,
PaulA.8 other authors1993; Oncogene-mediated propagation of tracheal epithelial cells from two cystic fibrosis fetuses with different mutations.Characterization of CFT-1 and CFT-2 cells in culture. Eur J Clin Invest 23:151–160[CrossRef]
QuX.-D,
LehrerR. I.1998; Secretory phospholipase A2 is the principal bactericide for staphylococci and other Gram-positive bacteria in human tears. Infect Immun 66:2791–2797
ValdasP,
BrowningJ,
EdelsonJ,
PruzanskiW.1993; Extracellular phospholipase A2 expression and inflammation: the relationship with associated disease states. J Lipid Mediat 8:1–30
WeinrauchY,
ElsbachP,
MadsenL. M,
ForemanA,
WeissJ.1996; The potent anti- Staphylococcus aureus activity of a sterile rabbit inflammatory fluid is due to a 14-kD phospholipase A2. J Clin Invest 97:250–257[CrossRef]